The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipeline productivity, and sustain a ROI on R&D spending needed for long-term drug development and commercial success. This means companies must look beyond current applications of commercial analytics focused mainly on tactical uses in an economic model framework designed to increase prescriptions. Successful best-in-breed companies will see the development and expansion of commercial analytics expertise as a key strategic asset to sustain a competitive advantage. The expansion of commercial analytics expertise must be applied in an interdisciplinary open system framework across the entire project/product lifecycle in response to a rapidly evolving pharmaceutical landscape.
Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.
Fill in your details to get a copy of this whitepaper, and contact us at firstname.lastname@example.org for any questions.